Summary: Teva and Barr's July cash-and-stock deal combined the world's largest and fourth-largest generics makers into one powerhouse. Teva gained Barr's strength in Central Europe and in fast-growing Eastern-European markets. In addition, the buyout expanded Teva's branded drug business. Barr has first-to-market rights for several new generics over the next few years, and it has a strong set of branded women's health treatments. The deal will help Teva achieve its strategic plan to reach $20 billion in sales with a 20 percent margin by 2012.